Trastuzumab biosimilar - Alteogen/Cristalia/Qilu Pharmaceutical

Drug Profile

Trastuzumab biosimilar - Alteogen/Cristalia/Qilu Pharmaceutical

Alternative Names: ALT 02; ALT L2

Latest Information Update: 27 Apr 2017

Price : $50

At a glance

  • Originator Alteogen
  • Developer Alteogen; Cristalia; Qilu Pharmaceutical
  • Class Antineoplastics; Monoclonal antibodies
  • Mechanism of Action ERBB 2 receptor antagonists; Immunomodulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase I Breast cancer; Gastric cancer

Most Recent Events

  • 26 Apr 2017 Phase-I clinical trials in Breast cancer in Canada (SC)
  • 26 Apr 2017 Phase-I clinical trials in Gastric cancer in Canada (SC)
  • 20 Apr 2017 Alteogen plans phase III trials and intends to seek marketing approval post their completion
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top